ASCENTAGE PHARM. DL-0001(36X)

Description: Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

---

Keywords: Biotechnology Cancer Pharmaceutical Solid Tumors Lymphoma Non Small Cell Lung Cancer Rental Services Small Cell Lung Cancer Advanced Solid Tumors Hematologic Malignancies Hematological Malignancies Venture Capital Investment Oncogenes Hodgkin Age Related Diseases Cancer Research Apoptosis Chronic Hbv Infection Chronic Hepatitis B Virus Neuroendocrine Tumor Programmed Cell Death Tyrosine Kinases Bcl 2 Apg 1252 Apg 1387 Inhibitor Of Apoptosis Philadelphia Chromosome Technology Promotion Services Therapies For Cancers Mdm2 Treatment Of Small Cell Lung Cancer

---

Home Page: www.ascentage.cn

Suzhou Industrial Park
Suzhou, 215000
China
Phone: 86 512 8555 7777

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)